Evidence map›Paper›PMID 40104058›Full record

ArticleiScience2025

Divergent responses to SARS-CoV-2 infection in bronchial epithelium with pre-existing respiratory diseases.

Justine Oliva, Manon Ruffin, Claire Calmel, Aurélien Gibeaud, Andrés Pizzorno, Clémence Gaudin, Solenne Chardonnet, Viviane de Almeida Bastos, Manuel Rosa-Calatrava, Antoine Soulé and 5 more

Abstract read
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Justine OlivaCIRI, Centre International de Recherche en Infectiologie, Team VirPath, Université de Lyon, INSERM U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, 69007 Lyon, France.
Manon RuffinSorbonne Université, INSERM, Centre de Recherche Saint-Antoine (CRSA), 75012 Paris, France.
Claire CalmelSorbonne Université, INSERM, Centre de Recherche Saint-Antoine (CRSA), 75012 Paris, France.
Aurélien GibeaudCIRI, Centre International de Recherche en Infectiologie, Team VirPath, Université de Lyon, INSERM U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, 69007 Lyon, France.
Andrés PizzornoCIRI, Centre International de Recherche en Infectiologie, Team VirPath, Université de Lyon, INSERM U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, 69007 Lyon, France.
Clémence GaudinSorbonne Université, INSERM, Centre de Recherche Saint-Antoine (CRSA), 75012 Paris, France.
Solenne ChardonnetSorbonne Université, INSERM, UMS PASS, Plateforme Post-génomique de la Pitié-Salpêtrière (P3S), 75013 Paris, France.
Viviane de Almeida BastosSorbonne Université, INSERM, UMS PASS, Plateforme Post-génomique de la Pitié-Salpêtrière (P3S), 75013 Paris, France.
Manuel Rosa-CalatravaCIRI, Centre International de Recherche en Infectiologie, Team VirPath, Université de Lyon, INSERM U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, 69007 Lyon, France.
Antoine SouléDepartment of Electrical and Computer Engineering, McGill University, Montréal, QC, Canada.
Amin EmadDepartment of Electrical and Computer Engineering, McGill University, Montréal, QC, Canada.
Simon RousseauThe Meakins-Christie Laboratories at the Research Institute of the McGill University Health Centre Research Institute, Department of Medicine, Faculty of Medicine, McGill University, Montréal, QC, Canada.
Harriet CorvolSorbonne Université, INSERM, Centre de Recherche Saint-Antoine (CRSA), 75012 Paris, France.
Olivier TerrierCIRI, Centre International de Recherche en Infectiologie, Team VirPath, Université de Lyon, INSERM U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, 69007 Lyon, France.
Loïc GuillotSorbonne Université, INSERM, Centre de Recherche Saint-Antoine (CRSA), 75012 Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pre-existing respiratory diseases may influence coronavirus disease (COVID-19) susceptibility and severity. However, the molecular mechanisms underlying the airway epithelial response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection severity in patients with chronic respiratory diseases remain unelucidated. Using an

Indexed as

MicrobiologyRespiratory medicineVirology

Identifiers

PMID40104058
PMCPMC11914195

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.